Physician profile
George Nahass
NPI 1215902986
$4,882.72
in general payments reported to CMS, 2019-2025
33 companies · $1,006 in 2025
The $1,006 reported for 2025 was more than what a typical Dermatopathology (Dermatology) provider received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,387 · 2020: $440 · 2021: $49.72 · 2022: $400 · 2023: $757 · 2024: $842 · 2025: $1,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,605.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $701.32 | 2019-2025 | |
| Lilly USA, LLC | $597.07 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $466.94 | 2020-2025 | |
| Ucb, INC. | $338.30 | 2019-2025 | Bimzelx |
| Janssen Biotech, INC. | $334.41 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $305.86 | 2019-2025 | Libtayo, Dupixent |
| Amgen INC. | $238.84 | 2019-2025 | Otezla, Otezla |
| Genzyme Corporation | $184.67 | 2019-2025 | |
| Leo Pharma INC. | $176.46 | 2019-2025 | Adbry |
| Pfizer INC. | $175.17 | 2019-2025 | |
| Incyte Corporation | $172.13 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $170.24 | 2019-2023 | Odomzo, Blu-U, Ilumya |
| Celgene Corporation | $132.48 | 2019 | |
| Galderma Laboratories, L.P. | $124.24 | 2019-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $105.79 | 2023-2025 | Sotyktu |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $99.74 | 2019-2025 | Seysara, Klisyri |
| Genentech USA, INC. | $85.27 | 2019-2024 | Xolair |
| Allergan, INC. | $84.22 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $64.21 | 2019-2023 | Siliq |
| Journey Medical Corporation | $44.36 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.88 | 2023 | Spevigo |
| Mayne Pharma Commercial LLC | $32.92 | 2019-2024 | |
| Mimedx Group, INC. | $29.23 | 2024 | |
| Dusa Pharmaceuticals, INC. | $24.72 | 2019 | |
| Medtronic, INC. | $22.33 | 2021 | |
| Strata Skin Sciences, INC. | $21.64 | 2025 | Xtrac |
| Merz North America, INC. | $20.97 | 2019 | |
| Sensus Healthcare, INC. | $19.13 | 2024 | |
| Arcutis Biotherapeutics, INC. | $18.13 | 2025 | Zoryve |
| Organon LLC | $15.33 | 2025 | Vtama |
| Dermavant Sciences, INC. | $14.30 | 2024 | Vtama |
| Dermira, INC. | $12.36 | 2019 | |
| Janssen Scientific Affairs, LLC | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Nahass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.